VIP Study

SARS-CoV2 Vaccination immunogenicity
in Immunosuppressed inflammatory bowel disease Patients.

[VIP Study @VIPStudy1]

☀️☀️@VIPStudy1 is fully open at all sites ➡️ https://t.co/N9vVnZlIX3

📢IBD and no IBD folk ➡️ covid vaccination study.

✅Have you had 2 doses of 💉 < 92 days ago?
✅IBD patients 👉 on only:
Vedo
IFX
Aza/MP
Tofu
Uste
+ IFX + Aza/MP

Check out 👉https://t.co/2H3ggysoIA

[VIP Study @VIPStudy1]

Congratulations #Jamesalexander 🙌

[BSG @BritSocGastro]

Congratulations to Dr James Alexander on being awarded the @BSGTrainees Young Gastroenterologist of the Year Award 👏

[Crohn's & Colitis Research @CrohnsColitisR]

What's the relationship between mood and physical health, when it comes to Crohn's and Colitis?

The @mindbody_ibd is investigating that very question, and they're offering £15 worth of vouchers to those taking part.

Find out more 👇

https://t.co/IVZLmf7MHL

[VIP Study @VIPStudy1]

👀More data from @VIPStudy1

Main message for #IBDpatients -
✔️ get NEW boosters = protection against Omicron variants.

New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs.

#COVID19Ab
#IBD
@AGA_Gastro
@NickPowellLab

https://t.co/IXhWUmaTUt

[VIP Study @VIPStudy1]

👀More data from @VIPStudy1

Main message for #IBDpatients -
✔️ get NEW boosters = protection against Omicron variants.

New boosters especially ☑️☑️ for those on anti -TNF and tofacitinib drugs.

#COVID19Ab
#IBD
@AGA_Gastro
@NickPowellLab

[NickPowellLab @NickPowellLab]

Beautifully presented James Alexander. There is a lot of research fatigue around covid. REMEMBER covid vaccines work in IBD. Even when our drugs impair that response, further boosters “rescue’ the deficit. GET YOUR BOOSTER this Autumn.

[Ben Mullish @bhmullish]

Great to see Dr James Alexander @ImperialMDR @IHepatology presenting the latest results from the @VIPStudy1 at @my_ueg #UEGWeek, exploring immune responses after 3rd dose of #COVID19 vaccination in #IBD patients - paper on this now out in @LancetGastroHep: https://t.co/YtsKBNbfLM

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

The last of the late breakers is presented by James Alexander @ImperialMDR, with data from @VIPStudy1 looking at COVID-19 vaccine-induced antibody & T-cell responses in immunosuppressed patients with inflammatory bowel disease after the 3rd vaccine dose #UEGWeek #gitwitter #IBD

[Hugh Thomas @HepatologyHugh]

The latest @LancetGastroHep podcast is now online—I had the pleasure of speaking to James Alexander of @ImperialMDR about the latest @VIPStudy1 data on #COVID19 vaccine responses in patients with #IBD
Listen: https://t.co/XDTBhuxe0u
Paper: https://t.co/8llo7sJDbZ

[VIP Study @VIPStudy1]

@VIPStudy1 @NickPowellLab @tariqahmadIBD
In this edition of @LancetGastroHep #jamesalexander

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

Our latest issue is now available at https://t.co/bK6A0hWoAC - incl content on #water & #sanitation, #rectalcancer surgery, #colorectalcancer #screening, #ulcerativecolitis, #COVID19, #hepatocellularcarcinoma in sub-Saharan #Africa & more!

#gitwitter #livertwitter #medtwitter

[VIP Study @VIPStudy1]

Our very own #jamesalexander talking to @lancetGastroHep

👇👇👇👇

In conversation with... James Alexander https://t.co/9sOm9i14XX

[Rob Brierley @Rob__Brierley]

Latest findings from the @VIPStudy1: a third dose of SARS-CoV-2 vaccine resulted in antibody levels significantly higher than after the second dose in patients with #IBD, irrespective of type of immunosuppressive therapy (1/6)

https://t.co/D0ERnvyfhN #gitwitter #covid19

[Ben Mullish @bhmullish]

…and James is hard at work again! Now presenting his work in @NickPowellLab @ImperialMDR the influence of the gut #microbiome and #metabolome upon immune responses to #COVID19 vaccines in #IBD patients… preprint online here: https://t.co/CfDG2wlZxl @NPCUK1

[VIP Study @VIPStudy1]

Poster Prize! Well done James, #DDW2022

[Ben Mullish @bhmullish]

James Alexander @ImperialMDR presenting the work from him and @NickPowellLab from the @VIPStudy1, assessing impact of immune responses to #COVID19 vaccines in immunosuppressed #IBD patients - out now in full in @LancetGastroHep: https://t.co/JV0417EDmO

[Ben Mullish @bhmullish]

James Alexander @ImperialMDR presenting the work from him and @NickPowellLab from the @VIPStudy1, assessing impact of immune responses to #COVID19 vaccines in immunosuppressed #IBD patients - out now in full in @LancetGastroHep: https://t.co/JV0417EDmO

[Charlie Lees @charlie_lees]

Withdrawal of @BritSocGastro IBD risk grid for COVID severity @Gut_BMJ

• reassuring for patients, with
• vaccines, boosters and antivirals

"We predict that the disruption from the pandemic for individuals with IBD will largely be no different to the general population."

[NickPowellLab @NickPowellLab]

If you fancy hearing more about the gut and research we have been doing at Imperial - come along and join us. All welcome…

[Imperial Patient Experience Research Centre (PERC) @Imperial_PERC]

@CrohnsColitisUK @IBSnetwork @BowelResearch @BladderAndBowel @VOICE__Global @CommVoicesNWL

[Seb @ibdseb]

#ECCO22
⏺ impaired anti-S RBD antibodies with TNFi and Tofa
J Alexander with @VIPStudy1 study data

Full paper now published 👇

https://t.co/kNmBWqP9U5

[The Lancet Gastroenterology & Hepatology @LancetGastroHep]

James Alexander presents data from the @VIPStudy1 on
#COVID19 vaccine-induced antibody responses in patients with #IBD #ECCO2022 #GITwitter

[Laura Constable @LauraConstable3]

Tomorrow marks the start of #ECCO2022 and a busy few days for @NickPowellLab We have two talks in the main scientific programme: James Alexander with the latest @VIPStudy1 (Fri @ 15.44 CET, 14.44 GMT) and myself talking all things fistula! (Fri @ 14.30 CET, 13.30 GMT)